STOCK TITAN

Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Neutral)
Tags
DarioHealth Corp. (Nasdaq: DRIO) has secured two new contracts to provide integrated chronic condition management solutions for two employers, a national supply chain company, and a regional education organization. The contracts aim to improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension, and weight management needs. Dario's cardiometabolic suite, combined with intelligent technologies and data insights, offers highly personalized experiences to keep members engaged for optimal results. Employees taking a GLP-1 medication will benefit from tailored support for long-term behavior change.
DarioHealth Corp. (Nasdaq: DRIO) ha ottenuto due nuovi contratti per fornire soluzioni integrate di gestione delle condizioni croniche a due datori di lavoro, una compagnia nazionale della catena di approvvigionamento e un'organizzazione educativa regionale. I contratti hanno l'obiettivo di migliorare i risultati per i dipendenti con condizioni di salute cardiometaboliche, inclusi diabete, pre-diabete, ipertensione e necessità di gestione del peso. La suite cardiometabolica di Dario, abbinata a tecnologie intelligenti e analisi dei dati, offre esperienze altamente personalizzate per mantenere i membri coinvolti e ottenere risultati ottimali. I dipendenti che assumono un farmaco GLP-1 beneficeranno di un supporto su misura per un cambiamento comportamentale a lungo termine.
DarioHealth Corp. (Nasdaq: DRIO) ha asegurado dos nuevos contratos para proporcionar soluciones integradas de manejo de condiciones crónicas a dos empleadores, una compañía nacional de cadena de suministros y una organización educativa regional. Los contratos buscan mejorar los resultados para empleados con condiciones de salud cardiometabólicas, incluyendo diabetes, pre-diabetes, hipertensión y necesidades de manejo de peso. El conjunto de soluciones cardiometabólicas de Dario, junto con tecnologías inteligentes y perspectivas de datos, ofrece experiencias altamente personalizadas para mantener a los miembros comprometidos y lograr resultados óptimos. Los empleados que toman medicación GLP-1 se beneficiarán de un apoyo personalizado para el cambio de comportamiento a largo plazo.
DarioHealth Corp. (나스닥: DRIO)는 국가 공급망 회사와 지역 교육 기관인 두 고용주를 위한 만성 상태 관리 통합 솔루션을 제공하기 위해 두 개의 새로운 계약을 확보했습니다. 이 계약들은 당뇨병, 전당뇨, 고혈압 및 체중 관리가 필요한 직원들의 건강 결과를 개선하는 것을 목표로 합니다. Dario의 심혈관 대사 솔루션 스위트는 지능형 기술과 데이터 통찰력과 결합하여 최적의 결과를 위해 회원들이 계속 참여할 수 있도록 매우 개인화된 경험을 제공합니다. GLP-1 약물을 복용하는 직원들은 장기적인 행동 변화를 위한 맞춤형 지원을 받게 될 것입니다.
DarioHealth Corp. (Nasdaq: DRIO) a sécurisé deux nouveaux contrats pour fournir des solutions de gestion intégrée des maladies chroniques à deux employeurs, une entreprise nationale de la chaîne d'approvisionnement et une organisation régionale de l'éducation. Les contrats visent à améliorer les résultats pour les employés souffrant de problèmes de santé cardiometaboliques, y compris le diabète, le prédiabète, l'hypertension et les besoins en gestion du poids. La suite cardiometabolique de Dario, combinée à des technologies intelligentes et des insights de données, offre des expériences hautement personnalisées pour maintenir l'engagement des membres et obtenir des résultats optimaux. Les employés prenant un médicament GLP-1 bénéficieront d'un soutien personnalisé pour un changement de comportement à long terme.
DarioHealth Corp. (Nasdaq: DRIO) hat zwei neue Verträge abgeschlossen, um zwei Arbeitgebern, einem nationalen Lieferkettenunternehmen und einer regionalen Bildungsorganisation, integrierte Lösungen für das Management von chronischen Erkrankungen zu bieten. Die Verträge zielen darauf ab, die Ergebnisse für Mitarbeiter mit kardiometabolischen Gesundheitszuständen, einschließlich Diabetes, Prädiabetes, Bluthochdruck und Gewichtsmanagementbedarf, zu verbessern. Das kardiometabolische Produktportfolio von Dario, kombiniert mit intelligenten Technologien und Datenanalysen, bietet hochgradig personalisierte Erfahrungen, um Mitglieder für optimale Ergebnisse engagiert zu halten. Mitarbeiter, die GLP-1-Medikamente einnehmen, profitieren von maßgeschneiderter Unterstützung für langfristige Verhaltensänderungen.
Positive
  • None.
Negative
  • None.

Dario selected to provide integrated and proven solutions to improve employee cardiometabolic health

NEW YORK, April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024.

DarioHealth_Logo

The employers, a national supply chain company and a regional education organization, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1 medication.

Dario combines intelligent technologies with billions of data insights gathered from a decade of consumer engagement to deliver highly personalized experiences that keep members engaged over time for optimal results. Employees enrolled in Dario's cardiometabolic solution who are taking a GLP-1 medication will also have access to a tailored experience to support long-term behavior change.

"The trend towards integrated solutions continues to grow as employers look to reduce point solutions in favor of a single integrated solution that has a better member experience and has a lower cost of ownership when compared to managing multiple point solutions. Our new accounts are excited about Dario's proven ability to effectively engage people across multiple related conditions, and we look forward to delivering the market-leading results our clients deserve," said Rick Anderson, President of Dario. 

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected timing of the launch of the solutions and the benefits that may be realized by members using Dario's solutions. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact

Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280

DarioHealth Investor Relations Contact
 
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922

Media Contact

Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630

Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

 

 

Cision View original content:https://www.prnewswire.com/news-releases/dario-signs-two-employers-for-cardiometabolic-suite-with-integrated-glp-1-solution-302120847.html

SOURCE DarioHealth Corp.

FAQ

What contracts did DarioHealth Corp. (DRIO) secure recently?

DarioHealth Corp. (DRIO) secured contracts with a national supply chain company and a regional education organization to provide integrated chronic condition management solutions.

What health conditions will Dario's cardiometabolic suite address?

Dario's cardiometabolic suite will address conditions such as diabetes, pre-diabetes, hypertension, and weight management needs.

How does Dario deliver personalized experiences to members?

Dario combines intelligent technologies and data insights to deliver highly personalized experiences to keep members engaged for optimal results.

What support will employees taking a GLP-1 medication receive?

Employees taking a GLP-1 medication will have access to a tailored experience to support long-term behavior change.

Why are employers shifting towards integrated solutions?

Employers are shifting towards integrated solutions to reduce point solutions, provide a better member experience, and lower the cost of ownership compared to managing multiple point solutions.

DarioHealth Corp.

NASDAQ:DRIO

DRIO Rankings

DRIO Latest News

DRIO Stock Data

43.33M
23.92M
14.81%
29.43%
4.63%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About DRIO

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.